AR107441A1 - Forma cristalina de cobicistat - Google Patents

Forma cristalina de cobicistat

Info

Publication number
AR107441A1
AR107441A1 ARP170100170A ARP170100170A AR107441A1 AR 107441 A1 AR107441 A1 AR 107441A1 AR P170100170 A ARP170100170 A AR P170100170A AR P170100170 A ARP170100170 A AR P170100170A AR 107441 A1 AR107441 A1 AR 107441A1
Authority
AR
Argentina
Prior art keywords
cobicistat
crystal form
crystalline form
drxp
peaks
Prior art date
Application number
ARP170100170A
Other languages
English (en)
Inventor
Richard Hung Chiu Yu
Lok Him Lawrence Yu
Chiajen Lai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR107441A1 publication Critical patent/AR107441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una forma cristalina de un compuesto de fórmula (1). Reivindicación 2: Forma cristalina de la reivindicación 1, caracterizada por un patrón de difracción de rayos X en polvo (DRXP) que comprende picos a 17.2 ± 0.2 y 19.6 ± 0.2 (radiación de Cu Ka, expresada en grados 2q).
ARP170100170A 2016-01-28 2017-01-23 Forma cristalina de cobicistat AR107441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662288029P 2016-01-28 2016-01-28

Publications (1)

Publication Number Publication Date
AR107441A1 true AR107441A1 (es) 2018-05-02

Family

ID=57966186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100170A AR107441A1 (es) 2016-01-28 2017-01-23 Forma cristalina de cobicistat

Country Status (15)

Country Link
US (1) US20170217952A1 (es)
EP (1) EP3408261A1 (es)
JP (1) JP2019508393A (es)
KR (1) KR20180101589A (es)
CN (1) CN108834413A (es)
AR (1) AR107441A1 (es)
AU (2) AU2017211118B2 (es)
BR (1) BR112018014643A2 (es)
CA (1) CA3011930A1 (es)
EA (1) EA201891447A1 (es)
MA (1) MA46513A (es)
MX (1) MX2018009056A (es)
SG (1) SG11201806109RA (es)
TW (1) TW201728582A (es)
WO (1) WO2017132158A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
CN109384739B (zh) * 2017-08-14 2023-06-02 上海奥博生物医药股份有限公司 一种可比司他新晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2487165T (pt) * 2006-07-07 2016-11-18 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
EP2705027B1 (en) * 2011-05-02 2015-06-03 Gilead Sciences, Inc. Amorphous solid salts of Cobicistat (GS-9350)

Also Published As

Publication number Publication date
MX2018009056A (es) 2018-11-19
MA46513A (fr) 2019-08-21
CA3011930A1 (en) 2017-08-03
AU2017211118B2 (en) 2020-01-16
AU2019283825A1 (en) 2020-01-16
EA201891447A1 (ru) 2019-03-29
CN108834413A (zh) 2018-11-16
BR112018014643A2 (pt) 2018-12-11
EP3408261A1 (en) 2018-12-05
KR20180101589A (ko) 2018-09-12
US20170217952A1 (en) 2017-08-03
SG11201806109RA (en) 2018-08-30
AU2017211118A1 (en) 2018-08-09
WO2017132158A1 (en) 2017-08-03
JP2019508393A (ja) 2019-03-28
TW201728582A (zh) 2017-08-16

Similar Documents

Publication Publication Date Title
PE20201444A1 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MY180083A (en) Tetrahydropyrrolothiazine compounds
HRP20211670T1 (hr) Derivat difenilmetana u kristalnom obliku
PH12015502410A1 (en) Biheteroaryl compounds and uses thereof
DK201470447A (en) Crystal of flumioxazin
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
NZ743374A (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
CR20110457A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma
PT3541814T (pt) Compostos de amino-naft[1,2-d]imidazol-5-ona 2-substituída ou seus sais farmaceuticamente aceitáveis
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
PH12018500903A1 (en) Pyranodipyridine compound
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
EP3493921A4 (en) ROLL-TO-ROLL PROGRAMMABLE FILM IMPRESSION LITHOGRAPHY
AR107441A1 (es) Forma cristalina de cobicistat
AR108257A1 (es) Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
AR082435A1 (es) Valsartan altamente cristalino
AR112842A1 (es) Cristal de pirazina
AR099082A1 (es) Formas sólidas de tenofovir
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
AR103020A1 (es) Formas cristalinas de la sal de monosodio del foramsulfurón
MX2017003607A (es) Sales de clorhidrato de aluminio que exhiben un pico 1 sec alto.
AR095346A1 (es) Compuesto de hidrato de fluoreno y sus cristales

Legal Events

Date Code Title Description
FB Suspension of granting procedure